This study intended to analyze endocan levels as a marker of endothelial dysfunction in control group, first grade hypertension patients, second grade hypertension patients and end stage renal disease patients. Endocan levels were measured with ESM1 (Endocan) kit by Enzyme Linked Immunosorbent Assay (ELISA) method. This study used cross sectional method, conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from September to October 2017. The number of samples were 83, consist of 12 samples of control group, 22 samples of first degree hypertension, 28 samples of second grade hypertension, and 21 samples of end stage renal disease, aged 20-90 years old. This study showed significantly higher endocan levels in second grade hypertension patients and end stage renal disease patients (significantly; p<0,05). Endocan levels showed significantly higher (p<0,05) in end stage renal disease patients compared with control group and first degree hypertension patients; although it was not significantly (p>0,05) with second degree hypertension patients, but endocan levels median in end stage renal disease was higher than second degree hypertension patients (309,850 vs 273,050 ng/L).
Keywords: Endocan, Endothelial dysfunction, Hypertension, Chronic kidney disease